Handelsbanken Fonder AB Has $1.72 Million Position in DaVita Inc. (NYSE:DVA)

Handelsbanken Fonder AB trimmed its stake in DaVita Inc. (NYSE:DVA - Free Report) by 17.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,500 shares of the company's stock after selling 2,400 shares during the quarter. Handelsbanken Fonder AB's holdings in DaVita were worth $1,720,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in the stock. Transcendent Capital Group LLC bought a new position in DaVita during the third quarter valued at approximately $25,000. Blue Trust Inc. raised its position in DaVita by 56.4% during the third quarter. Blue Trust Inc. now owns 330 shares of the company's stock valued at $54,000 after acquiring an additional 119 shares in the last quarter. Quarry LP bought a new position in DaVita during the third quarter valued at approximately $60,000. Venturi Wealth Management LLC raised its position in DaVita by 59.8% during the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock valued at $61,000 after acquiring an additional 152 shares in the last quarter. Finally, Versant Capital Management Inc raised its position in DaVita by 58.7% during the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company's stock valued at $68,000 after acquiring an additional 169 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently weighed in on DVA shares. Barclays raised their price objective on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Cowen reiterated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price target on DaVita in a report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, DaVita presently has a consensus rating of "Hold" and an average target price of $166.33.

Remove Ads

DaVita Stock Performance

DVA stock traded up $1.09 during midday trading on Friday, hitting $147.83. 1,257,333 shares of the company traded hands, compared to its average volume of 876,483. DaVita Inc. has a twelve month low of $124.70 and a twelve month high of $179.60. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The business has a 50 day simple moving average of $160.66 and a 200-day simple moving average of $158.08. The stock has a market capitalization of $11.83 billion, a price-to-earnings ratio of 13.76, a price-to-earnings-growth ratio of 1.07 and a beta of 0.94.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. As a group, equities research analysts predict that DaVita Inc. will post 10.76 earnings per share for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.